[1]刘孟嘉,陈 文.伏硫西汀治疗抑郁症的药物经济学评价[J].卫生经济研究,2019,(12):53-58.
　LIU Meng-jia,CHEN Wen.Pharmacoeconomic Evaluation of Fluoxetine in the Treatment of Depression[J].Journal Press of Health Economics Research,2019,(12):53-58.
点击复制

伏硫西汀治疗抑郁症的药物经济学评价
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2019年12期
页码:
53-58
栏目:
药械管理
出版日期:
2019-11-29

文章信息/Info

Title:
Pharmacoeconomic Evaluation of Fluoxetine in the Treatment of Depression
作者:
刘孟嘉1; 陈 文1
１．复旦大学公共卫生学院，上海 200032
Author(s):
LIU Meng-jia; CHEN Wen
School of Public Health，Fudan University，Shanghai 200032，China
关键词:
抑郁症; 伏硫西汀; 决策树模型; 马尔可夫模型; 成本效用分析
Keywords:
depression; fluoxetine; decision tree model; Markov model; cost utility analysis
分类号:
R19
文献标志码:
A
摘要:
目的：评价新型多模式抗抑郁药伏硫西汀治疗抑郁症的成本与效用。方法：构建模拟时间为一年的决策树模型和马尔可夫模型，参数包括自杀风险、有效性参数、安全性参数、转换概率、效用参数、成本参数，输出结果包括总成本、质量调整生命年和增量成本效用比（ICER）。应用单因素敏感性分析和概率敏感性分析检验模型的稳健性。结果：与度洛西汀相比，伏硫西汀成本更高，获得的质量调整生命年也更高。从社会角度分析，ICER值为87 164元；从支付方角度分析，ICER值为92 987元，均高于2018年我国人均GDP。经单因素敏感性分析，价格是影响ICER值最敏感的因素之一，当伏硫西汀价格增加45%时，ICER值仍低于我国三倍人均GDP。经概率敏感性分析，当支付意愿为我国三倍人均GDP时，伏硫西汀具有成本效果的概率为61.9%。结论：与度洛西汀相比，伏硫西汀更具有效性和安全性，在治疗抑郁症方面更具成本效果。
Abstract:
Objective To evaluate the cost and utility of a new multi-modal antidepressant，fluoxetine，in the treatment of depression. Methods The decision tree model and Markov model with simulation time of one year were constructed. The output included total cost and quality adjusted life year，and incremental cost utility (ICER). Results Compared with duloxetine，fluoxetine was more costly and achieved a higher quality-adjusted life year. From a social perspective，the ICER value was 87 164 yuan；from the perspective of the payer，the ICER value was 92 987 yuan，which was higher than the per capita GDP of China in 2018. Through single factor sensitivity analysis，price was one of the most sensitive factors affecting ICER value. When the price of fluoxetine increases by 45%，the ICER value was still lower than China's triple GDP per capita. According to the probability sensitivity analysis，when the willingness to pay was three time of the GDP per capita in China，the probability of cost-effectiveness of fluoxetine was 61.9%. Conclusion Fluoxetine was more effective and safer than duloxetine and was more cost effective in treating depression.

参考文献/References:

[1] World Health Organization.Depression and other common mental disorders: global health estimates[M]. Geneva: World Health Organization，2017.
[2] World Health Organization (2012a). Depression: A Global Crisis. http://www.who.int/mental_health/management/depression/wfmh_ paper_depression_wmhd_2012.pdf.
[3] Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study[J]. The Lancet Psychiatry, 2019.
[4] Lundbeck. Vortioxetine cost-effectiveness model in patients with Major Depressive Disorder. 2015.
[5] 史春兰, 周建峰. 262例抑郁症自杀行为临床分析[J]. 临床精神医学杂志, 2001(1):31-32.
[6] UP TO Date 临床顾问.成人单相重性抑郁：初始治疗的选择[EB/OL].(2017-11-12) .https://www.uptodate.com/contents/zh-Hans/unipolar-major-depression-in-adults-choosing-initial-treatment#H432086717.
[7] Wang G, Gislum M, Filippov G, et al. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study[J]. Current medical research and opinion, 2015, 31(4): 785-794.
[8] 郝晓楠, 杨甫德, 况伟宏, 等. 盐酸度洛西汀肠溶片与帕罗西汀治疗重性抑郁障碍的多中心, 随机, 双盲, 平行对照研究[J]. 中国新药杂志, 2014, 23(23): 2767-2771.
[9] Lee P, Shu L, Xu X, et al. Once daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double‐blind, randomized, paroxetine controlled, non inferiority trial in China, Korea, Taiwan and Brazil[J]. Psychiatry and Clinical Neurosciences, 2007, 61(3): 295-307.
[10] Lundbeck. Vortioxetine Economic Model - Vortioxetine data: Long-term adverse events. 2014-07-15.
[11] Cipriani A, Furukawa T A, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis[J]. The lancet, 2009, 373(9665): 746-758.
[12] Wang Gang, Kristin Hui Xian Tan, Carol Liu, et al. Quality of Life and Healthcare Resource Use in Patients with Major Depressive Disorder in China: Results from the PROACT Study[C].Ispor Asia, 2018.
[13] Sullivan P W, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions[J]. CNS drugs, 2004, 18(13): 911-932.

更新日期/Last Update: 2019-11-29